Share Twitter LinkedIn Facebook Email George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving viagenpumatucel-L plus nivolumab. Read here:Â https://www.heatbio.com/news-media/news-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for
FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment Non-Small Cell Lung Cancer 5 Mins Read
Plasma ctDNA Kinetics as a Predictor of Systemic Therapy Response in Advanced NSCLC Non-Small Cell Lung Cancer 3 Mins Read
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 Non-Small Cell Lung Cancer 2 Mins Read